# Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

> **NCT00583024** · PHASE2 · COMPLETED · sponsor: **David M Lubaroff** · enrollment: 32 (actual)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **BIOLOGICAL:** ADENOVIRUS/PSA VACCINE

## Key facts

- **NCT ID:** NCT00583024
- **Lead sponsor:** David M Lubaroff
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2020-12-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00583024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00583024, "Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00583024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*